Clovis Oncology, Inc.
CLVSDelisted Dec 29, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001466301
Clovis Oncology, Inc. was delisted on Dec 29, 2022; its insiders filed their last Form 4 on Nov 3, 2022; 103 institutions reported holding it in 13F filings for Q3 2022, worth $42.6M in total; no superinvestor held it.
Q3 2022 vs. Q2 2022
How the institutions holding Clovis Oncology, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 116 | 1 | 103 | −12 |
| Shares | 42.2M | 166 | 35.8M | −6.47M (−15.3%) |
| Value | $76.0M | $299 | $42.6M | −$33.5M (−44.0%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Clovis Oncology, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 533,501 | $635.0K | 0.42% |
| Natixis | 500,000 | $600.0K | 0.00% |
| Gsa Capital Partners LLP | 399,039 | $475.0K | 0.06% |
| Susquehanna Fundamental Investments, LLC | 115,299 | $137.0K | 0.00% |
| Virtu Financial LLC | 53,447 | $64.0K | 0.01% |
| D. E. Shaw & Co., Inc. | 44,924 | $53.0K | 0.00% |
| Wolverine Asset Management LLC | 40,516 | $48.0K | 0.00% |
| Qube Research & Technologies Ltd | 20,078 | $24.0K | 0.00% |
| Future Financial Wealth Managment LLC | 13,500 | $24.0K | 0.03% |
| Toronto Dominion Bank | 2,307 | $3.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 1,353 | $2.00K | 0.00% |
| IFP Advisors, Inc | 10,000 | – | – |
Sold out (24)
Institutions that held Clovis Oncology, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Ergoteles LLC | 707,300 | $1.27M |
| Group One Trading, L.P. | 237,835 | $428.0K |
| Caption Management, LLC | 182,455 | $328.0K |
| HRT Financial LP | 130,830 | $235.0K |
| Simplex Trading, LLC | 99,358 | $178.0K |
| Two Sigma Investments, LP | 74,712 | $134.0K |
| Two Sigma Advisers, LP | 49,400 | $89.0K |
| Wolverine Trading, LLC | 45,133 | $77.0K |
| Balyasny Asset Management LLC | 26,841 | $48.0K |
| First Republic Investment Management, Inc. | 22,000 | $40.0K |
| Teacher Retirement System of Texas | 18,624 | $34.0K |
| Ameriprise Financial Inc | 15,330 | $28.0K |
| Kalos Management, Inc. | 10,500 | $21.0K |
| Y-Intercept (Hong Kong) Ltd | 11,630 | $21.0K |
| Cubist Systematic Strategies, LLC | 10,367 | $19.0K |
| blooom, inc. | 10,000 | $18.0K |
| Prospera Financial Services Inc | 9,150 | $16.0K |
| Spire Wealth Management | 4,000 | $7.00K |
| New York State Common Retirement Fund | 1,182 | $2.00K |
| Point72 Hong Kong Ltd | 1,267 | $2.00K |
| Huntington National Bank | 800 | $1.00K |
| Captrust Financial Advisors | 30 | $0 |
| Cypress Capital Management LLC (WY) | 200 | $0 |
| Elequin Capital LP | 12 | $0 |
Not filed for Q3 2022 yet (1)
Institutions that held Clovis Oncology, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Exane Derivatives | 166 | $299 |